How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

112,665 results for

Treating Family Members

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

121. Online Mindfulness for Women Treated for Breast Cancer and Men Treated for Prostate Cancer

assessed by The Self-Compassion Scale (SCS) Quality of Life [ Time Frame: Change from baseline until post treatment (10 weeks after baseline) and 6 months post treatment ] Change in Quality of Life assessed by the World Health Organization Well-being index (WHO-5) Eligibility Criteria Go to Information from the National Library of Medicine Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn (...) Online Mindfulness for Women Treated for Breast Cancer and Men Treated for Prostate Cancer Online Mindfulness for Women Treated for Breast Cancer and Men Treated for Prostate Cancer - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more

2017 Clinical Trials

122. Study of Treat to Target Versus Routine Care Maintenance Strategies in Crohn's Disease Patients Treated With Ustekinumab

to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Layout table for eligibility information Ages Eligible for Study: 18 Years and older (Adult, Older Adult) Sexes Eligible for Study: All Accepts Healthy Volunteers: No Criteria Inclusion Criteria: Main Study: Have active (...) Study of Treat to Target Versus Routine Care Maintenance Strategies in Crohn's Disease Patients Treated With Ustekinumab Study of Treat to Target Versus Routine Care Maintenance Strategies in Crohn's Disease Patients Treated With Ustekinumab - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum

2017 Clinical Trials

123. Study of Efficacy of CML-CP Patients Treated With ABL001 Versus Bosutinib, Previously Treated With 2 or More TKIs

decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Layout table for eligibility information Ages Eligible for Study: 18 Years and older (Adult, Older Adult) Sexes Eligible for Study: All Accepts Healthy Volunteers: No Criteria Inclusion Criteria: Male or female patients with a diagnosis of CML-CP ≥ 18 years of age (...) Study of Efficacy of CML-CP Patients Treated With ABL001 Versus Bosutinib, Previously Treated With 2 or More TKIs Study of Efficacy of CML-CP Patients Treated With ABL001 Versus Bosutinib, Previously Treated With 2 or More TKIs - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved

2017 Clinical Trials

124. Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer

-of-rights). Page 2 of 18Contents Contents 1 Recommendations 4 2 The technology 5 3 Evidence 6 4 Committee discussion 7 Clinical effectiveness 9 Cost effectiveness 10 Innovation 12 End-of-life considerations 13 Conclusions 14 5 Implementation 16 6 Appraisal committee members and NICE project team 17 Appraisal committee members 17 NICE project team 17 Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer (TA509) © NICE 2018. All rights reserved. Subject to Notice of rights (...) enquiries from NHS organisations about the commercial access agreement should be directed to global.pas@roche.com. Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer (TA509) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 16 of 186 6 Appr Appraisal committee members and NICE project team aisal committee members and NICE project team Appraisal committee members The technology appraisal

2018 National Institute for Health and Clinical Excellence - Technology Appraisals

125. Daratumumab monotherapy for treating relapsed and refractory multiple myeloma

of 31Contents Contents 1 Recommendations 4 2 Information about daratumumab 5 3 Evidence 6 4 Committee discussion 7 Nature of the condition 7 Clinical pathway 7 Clinical effectiveness 8 Cost effectiveness 16 Innovation 20 End-of-life considerations 21 Cancer Drugs Fund considerations 21 Summary of appraisal committee's key conclusions 24 5 Implementation 29 6 Appraisal committee members and NICE project team 30 Appraisal committee members 30 NICE project team 30 Daratumumab monotherapy for treating relapsed (...) Daratumumab monotherapy for treating relapsed and refractory multiple myeloma Dar Daratumumab monother atumumab monotherap apy for treating y for treating relapsed and refr relapsed and refractory multiple actory multiple m my yeloma eloma T echnology appraisal guidance Published: 14 March 2018 nice.org.uk/guidance/ta510 © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our responsibility

2018 National Institute for Health and Clinical Excellence - Technology Appraisals

126. Pirfenidone for treating idiopathic pulmonary fibrosis

discussion 7 Review objectives 7 Current practice 7 Comparators 8 Clinical effectiveness 8 Cost effectiveness 11 Cost-effectiveness results and conclusions 16 Potential equality issues 18 The Pharmaceutical Price Regulation Scheme 19 Summary of appraisal committee's key conclusions 19 5 Implementation 24 6 Appraisal committee members, guideline representatives and NICE project team 25 Appraisal committee members 25 NICE project team 25 Pirfenidone for treating idiopathic pulmonary fibrosis (TA504) © NICE (...) Pirfenidone for treating idiopathic pulmonary fibrosis Pirfenidone for treating idiopathic Pirfenidone for treating idiopathic pulmonary fibrosis pulmonary fibrosis T echnology appraisal guidance Published: 6 February 2018 nice.org.uk/guidance/ta504 © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our responsibility The recommendations in this guidance represent the view of NICE, arrived

2018 National Institute for Health and Clinical Excellence - Technology Appraisals

127. Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma

for data collection 19 6 Appraisal committee members and NICE project team 20 Appraisal committee members 20 NICE project team 20 Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma (TA505) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 3 of 211 1 Recommendations Recommendations 1.1 Ixazomib, with lenalidomide and dexamethasone, is recommended for use within the Cancer (...) -1 clinical trial. Data on overall survival and time-on- treatment will be collected through other sources including the Systemic Anti- Cancer Therapy (SACT) dataset. Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma (TA505) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 19 of 216 6 Appr Appraisal committee members and NICE project team aisal committee members

2018 National Institute for Health and Clinical Excellence - Technology Appraisals

128. Ibrutinib for treating relapsed or refractory mantle cell lymphoma

3 Evidence 6 4 Committee discussion 7 Clinical effectiveness 7 Cost effectiveness 11 End-of-life considerations 13 Potential equality issues 14 Pharmaceutical Price Regulation Scheme (PPRS) 2014 14 Summary of appraisal committee's key conclusions 14 5 Implementation 20 6 Appraisal committee members and NICE project team 21 Appraisal committee members 21 NICE project team 21 Ibrutinib for treating relapsed or refractory mantle cell lymphoma (TA502) © NICE 2018. All rights reserved. Subject (...) Ibrutinib for treating relapsed or refractory mantle cell lymphoma Ibrutinib for treating relapsed or Ibrutinib for treating relapsed or refr refractory mantle cell lymphoma actory mantle cell lymphoma T echnology appraisal guidance Published: 31 January 2018 nice.org.uk/guidance/ta502 © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our responsibility The recommendations in this guidance

2018 National Institute for Health and Clinical Excellence - Technology Appraisals

129. Strimvelis for treating adenosine deaminase deficiency?severe combined immunodeficiency

cell donor is available. Wh Why the committee made this recommendation y the committee made this recommendation ADA–SCID is a rare and serious condition that is fatal if untreated, and which severely affects the quality of life of people with the condition and their families. Treatment for ADA–SCID includes haematopoietic stem cell transplants (HSCTs). Clinical trial evidence shows that Strimvelis is effective in treating ADA–SCID. Compared with HSCTs, results suggest the main benefits (...) condition that also severely affects the lives of families and carers. Strimvelis for treating adenosine deaminase deficiency–severe combined immunodeficiency (HST7) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 8 of 31Diagnosis and management Diagnosis and management 4.3 The committee heard from clinical experts that, when ADA–SCID is suspected, people will be referred to 1 of the 2 expert centres in England, where

2018 National Institute for Health and Clinical Excellence - Highly specialised technology

130. Eribulin for treating locally advanced or metastatic breast cancer after 1 chemotherapy regimen

://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2 of 17Contents Contents 1 Recommendations 4 2 The technology 6 3 Committee discussion 7 Symptoms and management of advanced breast cancer 7 Clinical trial evidence 8 The economic model 11 Clinical parameters 11 Costs 14 Cost-effectiveness estimates 14 End of life 15 Other factors 15 4 Appraisal committee members and NICE project team 16 Appraisal committee members 16 NICE project team 16 Eribulin for treating locally advanced or metastatic breast (...) and convenient administration method. However, the committee concluded that it could not identify any specific health-related benefit that had not already been captured in the QAL Y calculation. Eribulin for treating locally advanced or metastatic breast cancer after 1 chemotherapy regimen (TA515) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 15 of 174 4 Appr Appraisal committee members and NICE project team aisal

2018 National Institute for Health and Clinical Excellence - Technology Appraisals

131. Avelumab for treating metastatic Merkel cell carcinoma

6 Appraisal committee members and NICE project team 23 Appraisal committee members 23 NICE project team 23 Avelumab for treating metastatic Merkel cell carcinoma (TA517) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 3 of 241 1 Recommendations Recommendations 1.1 Avelumab is recommended as an option for treating metastatic Merkel cell carcinoma in adults, only if they have had 1 or more lines of chemotherapy (...) Avelumab for treating metastatic Merkel cell carcinoma A Av velumab for treating metastatic Merk elumab for treating metastatic Merkel el cell carcinoma cell carcinoma T echnology appraisal guidance Published: 11 April 2018 nice.org.uk/guidance/ta517 © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our responsibility The recommendations in this guidance represent the view of NICE, arrived

2018 National Institute for Health and Clinical Excellence - Technology Appraisals

132. Ocrelizumab for treating relapsing?remitting multiple sclerosis

responsible for their care thinks that ocrelizumab is the right treatment, it should be available for use, in line with NICE's recommendations. Ocrelizumab for treating relapsing–remitting multiple sclerosis (TA533) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 20 of 225 5 Appr Appraisal committee members and NICE project team aisal committee members and NICE project team Appraisal committee members The 4 technology (...) Ocrelizumab for treating relapsing?remitting multiple sclerosis Ocrelizumab for treating Ocrelizumab for treating relapsing–remitting multiple sclerosis relapsing–remitting multiple sclerosis T echnology appraisal guidance Published: 25 July 2018 nice.org.uk/guidance/ta533 © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our responsibility The recommendations in this guidance represent the view

2018 National Institute for Health and Clinical Excellence - Technology Appraisals

133. Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine

Resource use 16 Treatment after disease progression 17 Revised base case 17 Cost-effectiveness results 18 Uncaptured benefits 18 End of life 19 Conclusions 20 Other factors 22 4 Implementation 23 5 Appraisal committee members and NICE project team 24 Appraisal committee members 24 NICE project team 24 Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine (TA535) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms (...) Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine L Len envatinib and sor vatinib and sorafenib for treating afenib for treating differentiated th differentiated thyroid cancer after yroid cancer after r radioactiv adioactive iodine e iodine T echnology appraisal guidance Published: 8 August 2018 nice.org.uk/guidance/ta535 © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y

2018 National Institute for Health and Clinical Excellence - Technology Appraisals

134. Dupilumab for treating moderate to severe atopic dermatitis

and NICE project team 20 Appraisal committee members 20 NICE project team 20 Dupilumab for treating moderate to severe atopic dermatitis (TA534) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 3 of 211 1 Recommendations Recommendations 1.1 Dupilumab is recommended as an option for treating moderate to severe atopic dermatitis in adults, only if: the disease has not responded to at least 1 other systemic therapy (...) Dupilumab for treating moderate to severe atopic dermatitis Dupilumab for treating moder Dupilumab for treating moderate to ate to se sev vere atopic dermatitis ere atopic dermatitis T echnology appraisal guidance Published: 1 August 2018 nice.org.uk/guidance/ta534 © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our responsibility The recommendations in this guidance represent the view of NICE

2018 National Institute for Health and Clinical Excellence - Technology Appraisals

135. Beta interferons and glatiramer acetate for treating multiple sclerosis

and glatiramer acetate for treating multiple sclerosis (TA527) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 3 of 29Appraisal committee members 28 NICE project team 28 Beta interferons and glatiramer acetate for treating multiple sclerosis (TA527) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 4 of 29This guidance replaces TA32. 1 1 (...) Beta interferons and glatiramer acetate for treating multiple sclerosis Beta interferons and glatir Beta interferons and glatiramer acetate amer acetate for treating multiple sclerosis for treating multiple sclerosis T echnology appraisal guidance Published: 27 June 2018 nice.org.uk/guidance/ta527 © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our responsibility The recommendations

2018 National Institute for Health and Clinical Excellence - Technology Appraisals

136. Dinutuximab beta for treating neuroblastoma

and debilitating, with severe and long-lasting side effects (including hearing loss, organ dysfunction, sterility, lack of growth, early onset of puberty, permanent disability, and secondary malignancies). The clinical and patient experts stated that a child's death has a significant effect on family members. The committee noted that treatment can involve many hospital visits and stays causing disruption to school, work and family life. It understood that parents and carers also have anxiety, emotional (...) acknowledged that there were uncaptured Dinutuximab beta for treating neuroblastoma (TA538) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 20 of 25health-related benefits. These included reduced quality of life because of the effect of stress and depression caused by the disease on young patients and their families, as well as the devastating effects of bereavement on families. It discussed the need to balance

2018 National Institute for Health and Clinical Excellence - Technology Appraisals

137. Burosumab for treating X-linked hypophosphataemia in children and young people

Evaluation committee members 29 NICE project team 29 Burosumab for treating X-linked hypophosphataemia in children and young people (HST8) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 3 of 301 1 Recommendations Recommendations 1.1 Burosumab is recommended, within its marketing authorisation, for treating X-linked hypophosphataemia (XLH) with radiographic evidence of bone disease in children aged 1 year and over (...) to errors in phosphate sensing and increased levels of fibroblast growth factor 23 (FGF23). Excess FGF23 causes impaired phosphate conservation and excessive phosphate excretion. It also supresses vitamin D production, which causes reduced calcium and phosphate absorption. 2.2 Because XLH is a genetic condition, it often affects several members of a family. Skeletal abnormalities such as bowed or bent legs, below average height and irregular growth of the skull are early signs of XLH. Children may also

2018 National Institute for Health and Clinical Excellence - Highly specialised technology

138. Novel <i>MYOC</i> gene mutation in a Chinese family with primary open-angle glaucoma. (PubMed)

in combination with high-throughput sequencing and validated using Sanger sequencing. Phenotypic characterisation included investigation into patient medical history and physical examination.Eight (36.4%) family members harboured heterozygous Y437H mutation, of whom seven (87.5%) were glaucomatous and one (12.5%) had OHT. The mean age of POAG diagnosis was 30.85±7.13 years. The mean highest recorded intraocular pressure (IOP) was 46.57±6.53 mm Hg. They all had complained of symptoms associated with vision (...) Novel MYOC gene mutation in a Chinese family with primary open-angle glaucoma. To characterise the genotype(s), phenotype(s) and age-related penetrance of glaucoma in a Chinese family with primary open-angle glaucoma (POAG).Recruited from a Chinese family spanning four generations, 7 individuals with POAG, 1 with ocular hypertension (OHT) and 14 unaffected individuals were included in this study. Genotypic investigation included sequencing of mutation sites using a glaucoma panel

2019 British Journal of Ophthalmology

139. Contributions of Public Health in Reducing the Population Burden of Familial Hypercholesterolemia: Challenges and Opportunities

surveillance data may include morbidity and mortality associated with FH, as well as FH awareness among patients, family members, and providers Challenge: Absence of population-based surveillance systems and registries (like cancer) Opportunity: Registry and other sources of data can be expanded to provide population level information on FH Challenge: Absence of an FH surveillance “case definition” that can be used for tracking population health burden, and trends over time and in population subgroups (...) Contributions of Public Health in Reducing the Population Burden of Familial Hypercholesterolemia: Challenges and Opportunities Contributions of Public Health in Reducing the Population Burden of Familial Hypercholesterolemia: Challenges and Opportunities | | Blogs | CDC Search Form Controls TOPIC ONLY Search The CDC cancel submit Search Form Controls TOPIC ONLY Search The CDC cancel submit Note: Javascript is disabled or is not supported by your browser. For this reason, some items

2018 CDC Genomics and Health Impact Blog

140. Family-led rehabilitation after stroke in India (ATTEND): a randomised controlled trial. (PubMed)

Family-led rehabilitation after stroke in India (ATTEND): a randomised controlled trial. Most people with stroke in India have no access to organised rehabilitation services. The effectiveness of training family members to provide stroke rehabilitation is uncertain. Our primary objective was to determine whether family-led stroke rehabilitation, initiated in hospital and continued at home, would be superior to usual care in a low-resource setting.The Family-led Rehabilitation after Stroke (...) in India (ATTEND) trial was a prospectively randomised open trial with blinded endpoint done across 14 hospitals in India. Patients aged 18 years or older who had had a stroke within the past month, had residual disability and reasonable expectation of survival, and who had an informal family-nominated caregiver were randomly assigned to intervention or usual care by site coordinators using a secure web-based system with minimisation by site and stroke severity. The family members of participants

Full Text available with Trip Pro

2017 Lancet

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>